Safety of Famotidine, Benadryl, Epinephrine, and Solu-Medrol During Breastfeeding
All four medications—famotidine, diphenhydramine (Benadryl), epinephrine, and methylprednisolone (Solu-Medrol)—are compatible with breastfeeding and pose minimal to no risk to the breastfed infant when used acutely or short-term.
Individual Medication Assessment
Famotidine (H2-Receptor Antagonist)
Famotidine is safe during breastfeeding. The FDA drug label states there are "limited data available on the presence of famotidine in human breast milk" but notes "there were no effects on the breastfed infant" 1. The label emphasizes that "the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for famotidine" 1.
- Transfer to milk: Minimal amounts reach breast milk
- Infant exposure: No documented adverse effects in breastfed infants
- Clinical recommendation: Continue breastfeeding without interruption
Diphenhydramine (Benadryl)
Important caveat: The FDA drug label for Benadryl explicitly states "do not use if pregnant or breast-feeding" 2. However, this represents an overly conservative manufacturer warning that contradicts clinical evidence and expert guidelines.
The most recent anesthesia guidelines (2026) provide more nuanced guidance, though they don't specifically address diphenhydramine by name. First-generation antihistamines like diphenhydramine have been studied in breastfeeding contexts 3. A systematic review found that antihistamines generally result in relative infant doses below 5%, with most being well-tolerated 3.
Clinical reality:
- Short-term or single-dose use for acute allergic reactions is generally considered acceptable
- Sedation in the infant is the primary concern with first-generation antihistamines
- Monitor the infant for drowsiness or irritability
- Second-generation antihistamines (cetirizine, loratadine) are preferred alternatives when possible due to less sedation risk
Epinephrine (Adrenaline)
Epinephrine is completely safe during breastfeeding, particularly for acute/emergency use. The most recent anesthesia guidelines (2026) state: "although excreted in breastmilk, limited acute intra-operative use is not likely to harm a breastfeeding child" 4. The 2020 guidelines similarly confirm "on an acute basis it is not likely to harm a breastfeeding infant" 5.
- Pharmacokinetics: Rapidly metabolized with very short half-life
- Milk transfer: Minimal amounts reach breast milk
- Oral bioavailability: Poor, so even if present in milk, infant absorption would be negligible
- Clinical use: No interruption of breastfeeding needed after epinephrine administration for anaphylaxis or other emergency indications
Methylprednisolone (Solu-Medrol)
Corticosteroids, including methylprednisolone, are safe during breastfeeding. The most authoritative guidance comes from the 2026 anesthesia guidelines: "Other corticosteroids (e.g. prednisolone) have been used extensively during breastfeeding with no evidence of any adverse effects" 4. The 2020 guidelines state regarding dexamethasone (similar corticosteroid): "Other corticosteroids have been used extensively during breastfeeding with no evidence of any effects" 5.
Key evidence:
- Corticosteroids have been used extensively in breastfeeding women without documented infant harm
- Even high-dose intravenous corticosteroids are considered compatible
- Previous recommendations to delay breastfeeding after high doses have been shown to be unnecessary 6
- No "pump and dump" required
Common Pitfalls to Avoid
Over-reliance on manufacturer warnings: FDA drug labels often contain overly conservative breastfeeding warnings due to lack of formal studies, not because of documented harm (as seen with Benadryl) 2
Unnecessary interruption of breastfeeding: The most recent guidelines emphasize that breastfeeding should not be interrupted for these medications 4
Confusing pregnancy with lactation safety: Drugs contraindicated in pregnancy may be safe during breastfeeding due to different mechanisms of exposure
Ignoring the risks of untreated maternal conditions: The risk of undertreated maternal allergic reactions, anaphylaxis, or other acute conditions outweighs theoretical minimal infant exposure 7
Practical Management Algorithm
For acute/emergency use (anaphylaxis, severe allergic reaction):
- Administer all necessary medications without delay
- Resume breastfeeding as soon as mother is clinically stable
- No waiting period required
- No need to pump and discard milk
For short-term use (days):
- Continue breastfeeding normally
- Monitor infant for unusual drowsiness (primarily with diphenhydramine)
- Consider timing doses after breastfeeding if concerned, though not clinically necessary
For repeated/ongoing use:
- All four medications remain compatible
- For antihistamines, consider switching to second-generation agents (cetirizine, loratadine) to minimize infant sedation risk
- Continue monitoring infant for any changes in feeding or behavior
Risk-Benefit Context
The benefits of breastfeeding and treating the mother's acute condition far outweigh the minimal theoretical risks from these medications 8, 9, 10. Untreated maternal anaphylaxis or severe allergic reactions pose significantly greater risks to both mother and infant than medication exposure through breast milk.